KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Treasury Shares (2018 - 2026)

Aquestive Therapeutics has reported Treasury Shares over the past 8 years, most recently at $1.7 million for Q4 2025.

  • For Q4 2025, Treasury Shares fell 33.79% year-over-year to $1.7 million; the TTM value through Dec 2025 reached $1.7 million, down 33.79%, while the annual FY2025 figure was $1.7 million, 33.79% down from the prior year.
  • Treasury Shares for Q4 2025 was $1.7 million at Aquestive Therapeutics, down from $2.9 million in the prior quarter.
  • Over five years, Treasury Shares peaked at $3.3 million in Q2 2025 and troughed at $8000.0 in Q2 2021.
  • A 5-year average of $1.5 million and a median of $1.8 million in 2023 define the central range for Treasury Shares.
  • Biggest five-year swings in Treasury Shares: plummeted 68.18% in 2021 and later soared 2025.0% in 2022.
  • Year by year, Treasury Shares stood at $8000.0 in 2021, then skyrocketed by 1925.0% to $162000.0 in 2022, then skyrocketed by 1102.47% to $1.9 million in 2023, then skyrocketed by 33.98% to $2.6 million in 2024, then plummeted by 33.79% to $1.7 million in 2025.
  • Business Quant data shows Treasury Shares for AQST at $1.7 million in Q4 2025, $2.9 million in Q3 2025, and $3.3 million in Q2 2025.